Skip to Content

Firvanq Approval History

FDA Approved: Yes (First approved January 26, 2018)
Brand name: Firvanq
Generic name: vancomycin hydrochloride
Dosage form: for Oral Solution
Company: CutisPharma
Treatment for: Clostridial Infection, Enterocolitis

Firvanq (vancomycin hydrochloride) is an oral solution formulation of an approved tricyclic glycopeptide antibiotic for the treatment of Clostridium difficile associated diarrhea and Staphylococcus aureus enterocolitis.

Development History and FDA Approval Process for Firvanq

DateArticle
Jan 29, 2018Approval CutisPharma Announces FDA Approval of Firvanq (vancomycin) for Treatment of Clostridium Difficile Associated Diarrhea and Staphylococcus Aureus Colitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide